Figure 1.

Summary of the relative risk reduction (%) of new-onset type 2 diabetes in randomized, controlled clinical trials of prevention. Studies shown are the Da Qing IGT and Diabetes Study, which evaluated diet and exercise (Pan et al 1997); the Finnish Diabetes Prevention Study, which evaluated diet and exercise (Tuomilehto et al 2001); the Diabetes Prevention Program (DPP) studies, which evaluated diet and exercise or metformin (Knowler et al 2002); the Study To Prevent Non-Insulin-Dependent Diabetes Mellitus (STOP-NIDDM), which evaluated acarbose; Troglitazone in Prevention of Diabetes (TRIPOD), which evaluated Troglitazone; XENical in the Prevention of Diabetes in Obese Subjects (XENDOS), which evaluated the gastrointestinal lipase inhibitor orlistat (Torgerson et al 2004); and a meta-analysis of 10 trials of RAS blockade with either ACE inhibitors or ARBs (Scheen 2004a). (See text for study details.)